Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of GW906 (SAL0132) added to existing therapy in primary hypertension inadequately controlled by one or two drugs
CTR20263485Phase 2Active
- Sponsor
- Gowell
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GW906 in essential hypertension, sponsored by Gowell. Started Sep 2026; status: active.
02
Drugs
GW906
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20263485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263485.